Posts Tagged ‘dementia’

Science Daily: Almost 1/3 of U.S. nursing home residents received antipsychotic drugs as chemical restraints

Wednesday, June 2nd, 2010

Illinois Nursing Home Abuse Blog
By Levin & Perconti

Science Daily is reporting that a study shows that newly admitted elderly patients to nursing homes have a higher rate of being prescribed antipsychotic drugs than in previous years. This study found that in 2007, almost one-third of U.S. nursing home residents received antipsychotic drugs. The FDA has issued a warning that there is a great risk of death among older adults with dementia who are taking these agents to control behavioral symptoms. A recent clinical trial has concluded that the adverse effects of atypical antipsychotic drugs have outweighed the benefits of those with Alzheimer’s. This shows that many doctors are over prescribing these drugs, and it is having an adverse effect on patients.

The nursing home study found that about 30 percent of the residents in the study received at least one antipsychotic medication in 2006 and 32 percent of those did not have dementia or another indication that they needed to be on this medication. Some experts believe that the organizational culture of the nursing homes may encourage the prescribing of antipsychotic. Hopefully, the FDA warning and other studies will move the prescription statistics in the opposite direction. If not policies may have to target those nursing homes that have a high antipsychotic prescription rate so as to improve patient care. To read more about the nursing home study, please click the link.

Read entire article:  http://blog.levinperconti.com/2010/05/antipsychotic_medications_are.html

« Return to news items


  • Share/Bookmark

Earth Times: Neurologist Fred Baughman—Vets Sudden Deaths Due to Antidepressant & Antipsychotic Drugs

Monday, May 24th, 2010

EarthTimes.org
By Fred A. Baughman, Jr.
May 24, 2010

Fred A. Baughman Jr., MD today announced the results of his research into the “series” of veterans’ deaths acknowledged by the Surgeon General of the Army.

Upon reading the May 24, 2008, Charleston (WV) Gazette article “Vets Taking Post Traumatic Stress Disorder Drugs Die in Sleep,” Baughman began to investigate why these reported deaths were “different.”  And, why they were likely, the “tip of an iceberg.”

Andrew White, Eric Layne, Nicholas Endicott and Derek Johnson were four West Virginia veterans who died in their sleep in early 2008. Baughman’s research suggests that they did not commit suicide and did not “overdose” leading to coma as suggested by the military.  All were diagnosed with PTSD.  All seemed “normal” when they went to bed.  And, all were on Seroquel (an antipsychotic) Paxil (an antidepressant) and Klonopin (a benzodiazepine).

They were not comatose and unarousable ? with pulse and respirations or pulse intact, responsive to CPR, surviving transport to a hospital, frequently surviving.  These were sudden cardiac deaths.

At the time, Stan White, father of Andrew White knew of eight such cases in Kentucky, Ohio and West Virginia.

In a February 7, 2008 interview with the Chicago Tribune, Lt. Gen. Eric B. Schoomaker, the Army’s surgeon general, said there has been “a series, a sequence of deaths” in the new “warrior transition units.”

In April 2005, the FDA warned that Seroquel put elderly patients with dementia-related psychosis at increased risk of death.

On January 15, 2009, Ray et al, reported that antipsychotics double the risk of sudden cardiac death.  On March 17, 2009, Whang et al reported that antidepressants, as well, increase the rate of sudden cardiac deaths.

And yet, in an August 14, 2008 analysis of two of the four Charleston-area deaths, the Inspector General for Veterans Affairs concluded (Report No. 08-01377-185): “Although antipsychotic medications have been identified as possible causes of cardiac rhythm disturbances, a 2001 review…found no association with olanzapine (Zyprexa), quetiapine (Seroquel), or risperidone (Risperdal) and Torsades de Pointes (a fatal heart rhythm) or sudden death… we are unaware of any clinical practice guidelines recommending baseline or periodic electrocardiogram monitoring in young, healthy patients on quetiapine (Seroquel).”

However, in a literature review covering the years 2000-2007, entitled Sudden Cardiac Death Secondary to Antidepressant and Antipsychotic Drugs: [Expert Opinion on Drug Safety; 2008, Number 2, March 2008 , pp. 181-194(14)] Sicouri and Antzelevitch conclude: (1) “A number of antipsychotic and antidepressant drugs can increase the risk of ventricular arrhythmias and sudden cardiac death?” (2) “Antipsychotics can increase cardiac risk even at low doses whereas antidepressants do it generally at high doses or in the setting of drug combinations,” and (3) “These observations call for?an ECG at baseline and after drug administration.”

Read entire article:  http://www.earthtimes.org/articles/show/fred-a-baughman-jr-md,1312839.shtml

« Return to news items


  • Share/Bookmark

Feds say drug company’s illegal payments to doctors fueled antipsychotic drugs wrongly prescribed to kids

Friday, May 7th, 2010

Seattle Post-Intelligencer
May 6, 2010

AstraZeneca Pharmaceuticals LP will pay Washington state nearly $10 million for improperly marketing Seroquel, a drug used to treat schizophrenia and manic depression.

Federal and state officials say that AstraZeneca illegally paid for doctors to attend meetings at resorts, where those doctors would “advise” the drug maker about marketing messages for unapproved uses. Medical professionals were also paid to serve as authors of promotional articles and to conduct studies for unapproved uses of the drug.

An investigation shows that as a result of these activities, misleading information was distributed about Seroquel, reports the state Attorney General’s Office. This led health providers to wrongly prescribe the drug to children, adolescents, and dementia patients in long-term care facilities – costing publicly funded programs millions of dollars.

Seroquel and other drugs are purchased for recipients of Medicaid, a government program for low-income consumers. Seroquel is approved for the treatment of schizophrenia, bipolar disorder, also known as manic depression, and other conditions.

A government investigation showed that between Jan.1, 2001, through Dec. 31, 2006, the drug was wrongly promoted to treat aggression, Alzheimer’s, anger management, anxiety, attention-deficit hyperactivity disorder, dementia, and sleeplessness. Sequoel isn’t approved by the Food and Drug Administration to treat these conditions.

Read entire article:  http://blog.seattlepi.com/boomerconsumer/archives/204984.asp

« Return to news items


  • Share/Bookmark

Johnson & Johnson Internal Documents Reveal Unsavory & Potentially Illegal Marketing of Antipsychotic drug Risperdal

Friday, March 12th, 2010

InjuryBoard.com
By Jim Lewis
March 12, 2010

The multi-billion dollar drug company, Johnson & Johnson (J&J), has come under fire for allegedly violating the rules in their marketing of Risperdal, an antipsychotic drug. Back in 1999, the Food and Drug Administration (FDA) told J&J that their marketing materials for geriatric patients overstated Risperdals benefits and minimized risks, according to Bloomberg.com. In 2000, an internal business plan strategized a way to increase Risperdals market share by marketing the benefits for elderly dementia, an unapproved use.

This was described as one of the more egregious examples of marketing drugs to vulnerable patients by Jerry Avorn, who works at the Harvard Medical School. He went on to say, seeing such clear evidence in black and white of the details of a campaign like this is still pretty upsetting.

J&Js marketing of Risperdal could be illegal since current law states that drug companies cannot promote a drug for uses other than those approved by the FDA. At the time this marketing and business plan was crafted, Risperdal was only approved for psychotic disorders like schizophrenia, not for dementia.

Read entire article:  http://virginiabeach.injuryboard.com/fda-and-prescription-drugs/johnson-johnson-internal-documents-reveal-unsavory-and-potentially-illegal-marketing-of-risperdal.aspx?googleid=279316

« Return to news items


  • Share/Bookmark

Massachusetts joins federal lawsuit accusing Johnson & Johnson of paying kickbacks to push their antipsychotic drug

Thursday, March 11th, 2010

Fierce Pharma
By Tracy Staton
March 11, 2010

The Massachusetts attorney general joined that federal lawsuit accusing Johnson & Johnson of paying kickbacks to push the antipsychotic Risperdal and other drugs into nursing homes. AG Martha Coakley didn’t stop there; however, her office is also investigating other companies that market antipsychotics to nursing homes in the state.

At issue is whether drug companies are touting antipsychotic drugs for unapproved uses, such as dementia. The FDA has warned that use of the atypical antipsychotics in elderly dementia patients can increase the risk of death. “The inappropriate off-label marketing of antipsychotic drugs to nursing homes is a significant health and safety issue for our seniors,” Coakley says in a statement released by her office (as quoted by the Boston Globe). “We have taken strong action on this issue in the past and are continuing to monitor it very closely moving forward.”

Read entire article:  http://www.fiercepharma.com/story/massachusetts-joins-kickback-suit-against-j-j/2010-03-11

« Return to news items


  • Share/Bookmark

After $1.4 billion criminal fine for illegal marketing, Eli Lilly tries something new—promoting “ethical behavior”

Monday, March 8th, 2010

IndyStar.com
John Russell
March 8, 2010

Eli Lilly and Co. has agreed to add four new senior positions to “promote highly ethical and compliant behaviors” as part of a settlement of two lawsuits arising from the company’s illegal marketing and promotion of several drugs.

The Indianapolis drugmaker also has agreed to upgrade its policies and procedures to ensure that patient safety “shall be of paramount importance,” according to a government filing the company made today.

Last year, Lilly paid $1.4 billion, the largest criminal fine ever imposed on a U.S. corporation, over the illegal marketing of Zyprexa. The company also pleaded guilty to a misdemeanor and agreed to additional oversight to resolve a 5-year-old federal investigation.

Federal prosecutors had said Lilly unlawfully promoted Zyprexa for agitation, aggression, hostility, dementia, depression and generalized sleep disorder, although the drug was approved only for schizophrenia and bipolar disorder.

The company had also improperly marketed Evista, its osteoporosis drug, and Prozac, its antidepressant.

In response, several shareholders sued the company, claiming it breached fiduciary duty in connection with the illegal marketing, exposing Lilly to substantial risk of damage. The suits are known as “derivative claims” as they were brought by shareholders on behalf of the company, rather than on behalf of shareholders, seeking to force the company to take corrective steps.

Read entire article:  http://www.indystar.com/article/20100308/BUSINESS/3080383/Eli-Lilly-adding-four-ethics-watchdogs

« Return to news items


  • Share/Bookmark

2,500 in nursing homes put at risk of death from Antipsychotics (note: death risk applies to anyone on antipsychotics)

Monday, March 8th, 2010

Fox News
March 8, 2010

Federal officials say nearly 2,500 Massachusetts nursing home residents were given powerful antipsychotic drugs last year that were not intended or recommended for their medical condition.

The Boston Globe reports that data collected by the Centers for Medicare and Medicaid Services show that 28 percent of Massachusetts nursing home residents were given antipsychotics in 2009. Of that group, more than one out of every five did not have a medical condition that called for such treatment.

Federal officials say the drugs are often given to patients with dementia, which puts them at risk for serious side effects, even death.

An official with the organization that represents the state’s nursing homes acknowledges that the number is too high and says better training is needed.

Read article:  http://www.foxnews.com/story/0,2933,588391,00.html

« Return to news items


  • Share/Bookmark

Scandalous abuse of the elderly: 100,000 prescribed antipsychotics that double risk of death/triple risk of stroke

Monday, February 8th, 2010

The Daily Telegraph
By Rebecca Smith
February 7, 2010

Tens of thousands of vulnerable dementia patients are being prescribed ‘chemical cosh’ drugs in hospital wards in a ‘scandalous abuse’ of the elderly, ten leading health organisations have said in a letter to The Daily Telegraph.

Three quarters of nurses have seen people with dementia in general wards in hospital prescribed antipsychotic drugs that are known to double the risk of death and triple the risk of a stroke in these patients, research has shown.

It is the first time the scale of the abuse in hospital wards is exposed, following warnings that 100,000 dementia patients in care homes are prescribed the drugs leading to the deaths of 23,000 a year.

Ten leading charities, carers groups and experts have written to The Daily Telegraph saying: “We cannot stand by while this scandalous abuse of vulnerable citizens continues.”

Neil Hunt, Chief Executive of Alzheimer’s Society said: “The massive over prescription of antipsychotics to people with dementia is an abuse of human rights, causing serious side effects and increasing risk of death. These powerful drugs should only be used in a small number of cases. The Government must take action to ensure that these drugs are only ever used as a last resort.”

They have called on the government to publish its long-overdue review of the use of antipsychotics which ministers promised would be out in May of this year.

Read entire article:  http://www.telegraph.co.uk/health/healthnews/6264962/Scandalous-abuse-of-the-elderly-prescribed-antipsychotics-in-hospital-exposed.html

« Return to news items


  • Share/Bookmark

Advocates want new rules to protect abuse of nursing home patients with antipsychotic drugs

Wednesday, December 23rd, 2009

Tracy Staton
Fierce Pharma
December 22, 2009

Illinois advocacy groups are calling for an overhaul of antipsychotic drug use in nursing home residents. They want Gov. Pat Quinn’s nursing home task force to recommend tough new rules for the use of those drugs, including restrictions on doctors who prescribe them.

Apparently, that task force plans to take up the issue by targeting the misuse of psychotropic drugs in the homes. ”We want people to be safe and cared for in nursing homes, not threatened or unwillingly sedated,” task force chairman Michael Gelder told the Chicago Tribune. But some of the changes advocates want would require legislative action.

« Return to news items


  • Share/Bookmark

Antipsychotics Like Seroquel Blamed for Deaths and Strokes

Monday, November 16th, 2009

AboutLawsuits.com
November 16, 2009

According to a new report, side effects of antipsychotics, such as Seroquel, Zyprexa, Risperdal and Abilify, could be responsible for as many as 1,800 deaths and 1,620 strokes each year among the elderly with dementia in the United Kingdom.

The report, which was commissioned by the British government, found that the use of antipsychotics for dementia has been largely ineffective, resulting in improvement in only 20% of patients. As a result of the findings, the U.K. Department of Health has initiated plans to reduce the use of atypical antipsychotic drugs like Zyprexa, Risperdal, Abilify and Serquel for dementia in its own health system, and hopes that the reduction will be picked up by other nations as well.

There are an estimated 180,000 elderly people with dementia in the United Kingdom currently being treated with the antipsychotic drugs, according to the report’s author, Professor Sube Banerjee. However, only 36,000 were found to derive any benefit from the drugs.

“The findings of my review confirm that there are indeed significant issues in terms of quality of care and patient safety,” said Banerjee, professor of mental health at King’s College London Institute of Psychiatry, in a letter to the Minister of State that accompanied the report. “These drugs appear to be used too often in dementia and, at their likely level of use, potential benefits are most probably outweighed by their risks overall.”

Read entire article: http://www.aboutlawsuits.com/antipsychotics-for-dementia-blamed-for-deaths-6965/

« Return to news items


  • Share/Bookmark